SGMT SAGIMET BIOSCIENCES INC

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways, today announced its participation in the First Annual Goldman Sachs Catalyst Clinic. Management is scheduled to participate in a virtual fireside chat at 12:00 p.m. ET / 9:00 a.m. PT on Wednesday, December 6, 2023.

A live webcast of the fireside chat will be available and in the Investors & Media Section of Sagimet’s website at , with an archived replay available following the live event.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of NASH, for which there are no treatments currently approved in the United States or Europe. Denifanstat is currently being tested in FASCINATE-2, a Phase 2b clinical trial in NASH with liver biopsy as the primary endpoint. For additional information about Sagimet, please visit .

Contact:

Maria Yonkoski

ICR Westwicke

203-682-7167

   



EN
04/12/2023

Underlying

SGMTSAGIMET BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SAGIMET BIOSCIENCES INC

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.78
TBI TRUEBLUE INC.
LINC Lincoln Educati... ... (+18)

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

TBI TRUEBLUE INC.
LINC LINCOLN EDUCATIONAL SERVICES
IMAX IMAX CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
PATK PATRICK INDUSTRIES INC.
MEG. MEG ENERGY CORP.
HRTG HERITAGE INSURANCE HOLDINGS INC.
ELF E.L.F. BEAUTY INC.
PAYS PAYSIGN INC
RPRX ROYALTY PHARMA PLC CLASS A
IMTX IMMATICS N V (A)
CVAC CUREVAC NV
IHS IHS HLDG LTD
SGHC SUPER GROUP (SGHC) LIMITED
CMPO COMPOSECURE INC
FTREV FORTREA HOLDINGS INC.
SGMT SAGIMET BIOSCIENCES INC
PC PREMIUM CATERING HOLDINGS LIMITED
06/13/25 June 13, 2025 1 EN
 PRESS RELEASE
Free
SGMT SAGIMET BIOSCIE...

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Act...

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 2:00 PM ET. To register, . The event will feature key opinion leader (...

June 9, 2025 1 EN
 PRESS RELEASE
Free
SGMT SAGIMET BIOSCIE...

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat...

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, TVB-3567, that is planned to be developed for acne in the U.S. SAN MATEO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a cl...

June 4, 2025 1 EN
 PRESS RELEASE
Free
SGMT SAGIMET BIOSCIE...

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergi...

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 SAN MATEO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a virtual key opinion leader (KOL) event on Thursday, May 29, 2025 at 1:00 PM ET. To register, . The event will feat...

May 22, 2025 1 EN
 PRESS RELEASE
Free
SGMT SAGIMET BIOSCIE...

Sagimet Biosciences Reports First Quarter 2025 Financial Results and P...

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate up...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch